Rabbit Recombinant Monoclonal MEK1 phospho S298 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Immunogen corresponding to Synthetic Peptide within Human MAP2K1 phospho S298.
Preservative: 0.09% Sodium azide
Constituents: 99.71% PBS, 0.2% BSA
Flow Cyt | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µL for 106 Cells | Notes - |
Select an associated product type
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
MEK1, PRKMK1, MAP2K1, Dual specificity mitogen-activated protein kinase kinase 1, MAP kinase kinase 1, MAPKK 1, MKK1, ERK activator kinase 1, MAPK/ERK kinase 1, MEK 1
Rabbit Recombinant Monoclonal MEK1 phospho S298 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Immunogen corresponding to Synthetic Peptide within Human MAP2K1 phospho S298.
Preservative: 0.09% Sodium azide
Constituents: 99.71% PBS, 0.2% BSA
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
MEK1 also known as MAP2K1 is a dual-specificity kinase that plays a role in the MAPK/ERK pathway. It has a molecular weight of around 45 kDa. MEK1 phosphorylates and activates the extracellular signal-regulated kinases ERK1 and ERK2. MEK1 is expressed in various tissues but is especially abundant in brain and heart tissues. Researchers commonly measure MEK1 levels using techniques like MEK1 ELISA while phospho-MEK antibodies help analyze its activity state.
MEK1 impacts cell processes such as proliferation differentiation and survival. It does not work alone but forms a complex with other proteins to exert its function. MEK1 activity is tightly controlled by upstream activators and downstream targets. One of the key phosphorylation sites on MEK1 is at serine 298 often marked as MEK1 pS298. This phosphorylation indicates MEK1's activated state which is critical for its biological function.
MEK1 integrates signals within the MAPK/ERK pathway and interacts closely with RAF kinases upstream and ERK kinases downstream. This pathway modulates cellular responses to growth factors. MEK1 undergoes phosphorylation enhancing its activity and subsequently phosphorylates ERK proteins. Many studies isolate MEK1 activity using specific inhibitors such as the MEK1 inhibitor to dissect pathway dynamics. ERK inhibitor PD98059 also helps when studying parallel interactions with MEK1.
MEK1 mutations or dysregulation have links to several types of cancer including melanoma. These often involve changes that lead to continuous MEK1 activation contributing to uncontrolled cell growth. MEK1 involvement in the RASopathies also shows its connection to disorders characterized by heart and facial abnormalities. In cancer MEK1 works closely with the BRAF protein which often harbors mutations leading to disease progression showcasing MEK1 as a target for therapeutic intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of Hela cells unstained and treated with imatinib (blue) or stained and treated with imatinib (red) or treated with pervanadate (green) using ab278591.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com